Epidemiology of Alzheimer disease (original) (raw)

• Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 6, 158–194 (2010).
• McKhann, G. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939–944 (1984).
  CAS PubMed Google Scholar
• Ferri, C. P. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117 (2005).
  PubMed PubMed Central Google Scholar
• Pendlebury, S. T. & Rothwell, P. M. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 8, 1006–1018 (2009).
  PubMed Google Scholar
• Cheung, Z. H., Gong, K. & Ip, N. Y. Cyclin-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2. J. Neurosci. 28, 4872–4877 (2008).
  CAS PubMed PubMed Central Google Scholar
• Weishaupt, J. H. et al. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction. Mol. Cell. Neurosci. 24, 489–502 (2003).
  CAS PubMed Google Scholar
• Wen, Y. et al. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim. Biophys. Acta 1772, 473–483 (2007).
  CAS PubMed Google Scholar
• Kivipelto, M. et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56, 1683–1689 (2001).
  CAS PubMed Google Scholar
• Launer, L. J., Masaki, K., Petrovitch, H., Foley, D. & Havlik, R. J. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu–Asia Aging Study. JAMA 274, 1846–1851 (1995).
  CAS PubMed Google Scholar
• Swan, G. E., Carmelli, D. & Larue, A. Systolic blood pressure tracking over 25 to 30 years and cognitive performance in older adults. Stroke 29, 2334–2340 (1998).
  CAS PubMed Google Scholar
• Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C. & Yaffe, K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277–281 (2005).
  CAS PubMed Google Scholar
• Glynn, R. J. et al. Current and remote blood pressure and cognitive decline. JAMA 281, 438–445 (1999).
  CAS PubMed Google Scholar
• Knopman, D. et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56, 42–48 (2001).
  CAS PubMed Google Scholar
• Posner, H. B. et al. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 58, 1175–1181 (2002).
  CAS PubMed Google Scholar
• Skoog, I. et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141–1145 (1996).
  CAS PubMed Google Scholar
• Kalaria, R. N. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr. Rev. 68 (Suppl. 2), S74–S87 (2010).
  PubMed Google Scholar
• Deane, R., Wu, Z. & Zlokovic, B. V. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood–brain barrier. Stroke 35, 2628–2631 (2004).
  CAS PubMed Google Scholar
• Forette, F. et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur.) study. Arch. Intern. Med. 162, 2046–2052 (2002).
  PubMed Google Scholar
• Tzourio, C. et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 163, 1069–1075 (2003).
  CAS PubMed Google Scholar
• Starr, J. M., Whalley, L. J. & Deary, I. J. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J. Am. Geriatr. Soc. 44, 411–415 (1996).
  CAS PubMed Google Scholar
• Prince, M. J., Bird, A. S., Blizard, R. A. & Mann, A. H. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 312, 801–805 (1996).
  CAS PubMed PubMed Central Google Scholar
• [No authors listed] Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265, 3255–3264 (1991).
• Lithell, H. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21, 875–886 (2003).
  CAS PubMed Google Scholar
• Peters, R. et al. Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET). Age Ageing 39, 439–445 (2010).
  PubMed Google Scholar
• Leibson, C. L. et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann. N. Y. Acad. Sci. 826, 422–427 (1997).
  CAS PubMed Google Scholar
• Luchsinger, J. A., Tang, M. X., Stern, Y., Shea, S. & Mayeux, R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 154, 635–641 (2001).
  CAS PubMed Google Scholar
• Ott, A. et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937–1942 (1999).
  CAS PubMed Google Scholar
• Craft, S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4, 147–152 (2007).
  CAS PubMed Google Scholar
• Cook, D. G. et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ɛ4 allele. Am. J. Pathol. 162, 313–319 (2003).
  CAS PubMed PubMed Central Google Scholar
• Yamagishi, S., Nakamura, K., Inoue, H., Kikuchi, S. & Takeuchi, M. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease. Med. Hypotheses 64, 1205–1207 (2005).
  CAS PubMed Google Scholar
• Yan, S. D. et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685–691 (1996).
  CAS PubMed Google Scholar
• Harvey, J., Solovyova, N. & Irving, A. Leptin and its role in hippocampal synaptic plasticity. Prog. Lipid Res. 45, 369–378 (2006).
  CAS PubMed PubMed Central Google Scholar
• Li, X. L. et al. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113, 607–615 (2002).
  CAS PubMed Google Scholar
• Lieb, W. et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302, 2565–2572 (2009).
  CAS PubMed PubMed Central Google Scholar
• Profenno, L. A, Porsteinsson, A. P. & Faraone, S. V. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry 67, 505–512 (2010).
  PubMed Google Scholar
• Janson, J. et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474–481 (2004).
  CAS PubMed Google Scholar
• Peila, R., Rodriguez, B. L. & Launer, L. J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu–Asia Aging Study. Diabetes 51, 1256–1262 (2002).
  CAS PubMed Google Scholar
• Arvanitakis, Z. et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67, 1960–1965 (2006).
  CAS PubMed Google Scholar
• Reger, M. A. et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 27, 451–458 (2006).
  CAS PubMed Google Scholar
• Watson, G. S. et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13, 950–958 (2005).
  PubMed Google Scholar
• Risner, M. E. et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246–254 (2006).
  CAS PubMed Google Scholar
• Sato, T. et al. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2009.10.009.
  CAS PubMed Google Scholar
• Jiang, Q., Heneka, M. & Landreth, G. E. The role of peroxisome proliferator-activated receptor-gamma (PPARγ) in Alzheimer's disease: therapeutic implications. CNS Drugs 22, 1–14 (2008).
  CAS PubMed Google Scholar
• Grundman, M., Corey-Bloom, J., Jernigan, T., Archibald, S. & Thal, L. J. Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy. Neurology 46, 1585–1591 (1996).
  CAS PubMed Google Scholar
• White, H., Pieper, C. & Schmader, K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J. Am. Geriatr. Soc. 46, 1223–1227 (1998).
  CAS PubMed Google Scholar
• Gustafson, D., Rothenberg, E., Blennow, K., Steen, B. & Skoog, I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 163, 1524–1528 (2003).
  PubMed Google Scholar
• Razay, G. & Vreugdenhil, A. Obesity in middle age and future risk of dementia: midlife obesity increases risk of future dementia. BMJ 331, 455 (2005).
  PubMed PubMed Central Google Scholar
• Stewart, R. et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu–Asia Aging Study. Arch. Neurol. 62, 55–60 (2005).
  PubMed Google Scholar
• Gustafson, D. R. et al. Adiposity indicators and dementia over 32 years in Sweden. Neurology 73, 1559–1566 (2009).
  CAS PubMed PubMed Central Google Scholar
• Whitmer, R. A. et al. Central obesity and increased risk of dementia more than three decades later. Neurology 71, 1057–1064 (2008).
  CAS PubMed Google Scholar
• Muckle, T. J. & Roy., J. R. High-density lipoprotein cholesterol in differential diagnosis of senile dementia. Lancet 1, 1191–1193 (1985).
  CAS PubMed Google Scholar
• Kuo, Y. M. et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1–42 levels. Biochem. Biophys. Res. Commun. 252, 711–715 (1998).
  CAS PubMed Google Scholar
• Michikawa, M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J. Neurosci. Res. 72, 141–146 (2003).
  CAS PubMed Google Scholar
• Wieringa, G. E. et al. Apolipoprotein E genotypes and serum lipid levels in Alzheimer's disease and multi-infarct dementia. Int. J. Geriatr. Psychiatry 12, 359–362 (1997).
  CAS PubMed Google Scholar
• van Exel, E. et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann. Neurol. 51, 716–721 (2002).
  CAS PubMed Google Scholar
• Lesser, G. et al. Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 12, 138–145 (2001).
  CAS PubMed Google Scholar
• Burns, M. & Duff, K. Cholesterol in Alzheimer's disease and tauopathy. Ann. N. Y. Acad. Sci. 977, 367–375 (2002).
  CAS PubMed Google Scholar
• Jones, R. W. et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 4, 145–153 (2008).
  CAS PubMed Google Scholar
• Simons, M. et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346–350 (2002).
  CAS PubMed Google Scholar
• Sparks, D. L. et al. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand. Suppl. 185, 3–7 (2006).
  CAS PubMed Google Scholar
• Sano, M. Multi-center, randomized, double-blind, placebo-controlled trial of simvatatin to slow the progression of Alzheimer's disease. Alzheimers Dement. 4 (Suppl. 2), T200 (2008).
  Google Scholar
• Raffaitin, C. et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32, 169–174 (2009).
  PubMed PubMed Central Google Scholar
• Solfrizzi, V. et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J. Neurol. Neurosurg. Psychiatry 81, 433–440 (2010).
  PubMed Google Scholar
• Yaffe, K., Weston, A. L., Blackwell, T. & Krueger, K. A. The metabolic syndrome and development of cognitive impairment among older women. Arch. Neurol. 66, 324–328 (2009).
  PubMed PubMed Central Google Scholar
• Tyas, S. L. Are tobacco and alcohol use related to Alzheimer's disease? A critical assessment of the evidence and its implications. Addict. Biol. 1, 237–254 (1996).
  CAS PubMed Google Scholar
• Brenner, D. E. et al. Relationship between cigarette smoking and Alzheimer's disease in a population-based case–control study. Neurology 43, 293–300 (1993).
  CAS PubMed Google Scholar
• Ferini-Strambi, L., Smirne, S., Garancini, P., Pinto, P. & Franceschi, M. Clinical and epidemiological aspects of Alzheimer's disease with presenile onset: a case control study. Neuroepidemiology 9, 39–49 (1990).
  CAS PubMed Google Scholar
• Merchant, C. et al. The influence of smoking on the risk of Alzheimer's disease. Neurology 52, 1408–1412 (1999).
  CAS PubMed Google Scholar
• Launer, L. J. et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 52, 78–84 (1999).
  CAS PubMed Google Scholar
• Ott, A. et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 351, 1840–1843 (1998).
  CAS PubMed Google Scholar
• Doll, R., Peto, R., Boreham, J. & Sutherland, I. Smoking and dementia in male British doctors: prospective study. BMJ 320, 1097–1102 (2000).
  CAS PubMed PubMed Central Google Scholar
• Hebert, L. E. et al. Relation of smoking and alcohol consumption to incident Alzheimer's disease. Am. J. Epidemiol. 135, 347–355 (1992).
  CAS PubMed Google Scholar
• Cataldo, J. K., Prochaska, J. J. & Glantz, S. A. Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. J. Alzheimers Dis. 19, 465–480 (2010).
  PubMed PubMed Central Google Scholar
• Traber, M. G., van der Vliet, A., Reznick, A. Z. & Cross, C. E. Tobacco-related diseases. Is there a role for antioxidant micronutrient supplementation? Clin. Chest Med. 21, 173–187 (2000).
  CAS PubMed Google Scholar
• Kellar, K. J. & Wonnacott, S. in Nicotine Psychopharmacology: Molecular, Cellular, and Behavioral Aspects (eds Wonnacott, S., Russell, M. A. & Stolerman, I. P) 341–373 (Oxford University Press, Oxford, 1990).
  Google Scholar
• Jorm, A. F. History of depression as a risk factor for dementia: an updated review. Aust. NZ J. Psychiatry 35, 776–781 (2001).
  CAS Google Scholar
• Barnes, D. E., Alexopoulos, G. S., Lopez, O. L., Williamson, J. D. & Yaffe, K. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch. Gen. Psychiatry 63, 273–279 (2006).
  PubMed Google Scholar
• Becker, J. T. et al. Depressed mood is not a risk factor for incident dementia in a community-based cohort. Am. J. Geriatr. Psychiatry 17, 653–663 (2009).
  PubMed PubMed Central Google Scholar
• Panza, F. et al. Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging. Int. J. Geriatr. Psychiatry 23, 726–734 (2008).
  PubMed Google Scholar
• Aleisa, A. M., Alzoubi, K. H., Gerges, N. Z. & Alkadhi, K. A. Chronic psychosocial stress-induced impairment of hippocampal LTP: possible role of BDNF. Neurobiol. Dis. 22, 453–462 (2006).
  CAS PubMed Google Scholar
• Mayeux, R. et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45, 555–557 (1995).
  CAS PubMed Google Scholar
• Rasmusson, D. X., Brandt, J., Martin, D. B. & Folstein, M. F. Head injury as a risk factor in Alzheimer's disease. Brain Inj. 9, 213–219 (1995).
  CAS PubMed Google Scholar
• Schofield, P. W. et al. Alzheimer's disease after remote head injury: an incidence study. J. Neurol. Neurosurg. Psychiatry 62, 119–124 (1997).
  CAS PubMed PubMed Central Google Scholar
• Fleminger, S., Oliver, D. L., Lovestone, S., Rabe-Hesketh, S. & Giora, A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J. Neurol. Neurosurg. Psychiatry 74, 857–862 (2003).
  CAS PubMed PubMed Central Google Scholar
• Mortimer, J. A. et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case–control studies. EURODEM Risk Factors Research Group. Int. J. Epidemiol. 20 (Suppl. 2), S28–S35 (1991).
  PubMed Google Scholar
• Guo, Z. et al. Head injury and the risk of AD in the MIRAGE study. Neurology 54, 1316–1323 (2000).
  CAS PubMed Google Scholar
• Mehta, K. M. et al. Head trauma and risk of dementia and Alzheimer's disease: the Rotterdam Study. Neurology 53, 1959–1962 (1999).
  CAS PubMed Google Scholar
• Plassman, B. L. et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 55, 1158–1166 (2000).
  CAS PubMed Google Scholar
• Hartman, R. E. et al. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J. Neurosci. 22, 10083–10087 (2002).
  CAS PubMed PubMed Central Google Scholar
• Franz, G. et al. Amyloid β 1–42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 60, 1457–1461 (2003).
  CAS PubMed Google Scholar
• Morris, M. C. et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287, 3230–3237 (2002).
  CAS PubMed Google Scholar
• Engelhart, M. J. et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287, 3223–3229 (2002).
  CAS PubMed Google Scholar
• Masaki, K. H. et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54, 1265–1272 (2000).
  CAS PubMed Google Scholar
• Laurin, D., Masaki, K. H., Foley, D. J., White, L. R. & Launer, L. J. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu–Asia Aging Study. Am. J. Epidemiol. 159, 959–967 (2004).
  PubMed Google Scholar
• Luchsinger, J. A., Tang, M. X., Shea, S. & Mayeux, R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 60, 203–208 (2003).
  PubMed Google Scholar
• Huang, T. L. et al. Benefits of fatty fish on dementia risk are stronger for those without APOE ɛ4. Neurology 65, 1409–1414 (2005).
  CAS PubMed Google Scholar
• Kalmijn, S. et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 42, 776–782 (1997).
  CAS PubMed Google Scholar
• Schaefer, E. J. et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol. 63, 1545–1550 (2006).
  PubMed Google Scholar
• Roberts, R. O. et al. Polyunsaturated fatty acids and reduced odds of MCI: the Mayo Clinic Study of Aging. J. Alzheimers Dis. 21, 853–865.
  CAS PubMed Google Scholar
• Solfrizzi, V. et al. Dietary intake of unsaturated fatty acids and age-related cognitive decline: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. Neurobiol. Aging 27, 1694–1704 (2006).
  CAS PubMed Google Scholar
• Engelhart, M. J. et al. Diet and risk of dementia: does fat matter?: The Rotterdam Study. Neurology 59, 1915–1921 (2002).
  CAS PubMed Google Scholar
• Scarmeas, N., Stern, Y., Tang, M. X., Mayeux, R. & Luchsinger, J. A. Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. 59, 912–921 (2006).
  PubMed PubMed Central Google Scholar
• Scarmeas, N. et al. Mediterranean diet and mild cognitive impairment. Arch. Neurol. 66, 216–225 (2009).
  PubMed PubMed Central Google Scholar
• Scarmeas, N. et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 302, 627–637 (2009).
  CAS PubMed PubMed Central Google Scholar
• Scarmeas, N., Stern, Y., Mayeux, R. & Luchsinger, J. A. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol. 63, 1709–1717 (2006).
  PubMed PubMed Central Google Scholar
• Feart, C. et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302, 638–648 (2009).
  CAS PubMed PubMed Central Google Scholar
• Anstey, K. J., Mack, H. A. & Cherbuin, N. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am. J. Geriatr. Psychiatry 17, 542–555 (2009).
  PubMed Google Scholar
• Kang, J. H., Cook, N., Manson, J., Buring, J. E. & Grodstein, F. A randomized trial of vitamin E supplementation and cognitive function in women. Arch. Intern. Med. 166, 2462–2468 (2006).
  CAS PubMed Google Scholar
• Yaffe, K., Clemons, T. E., McBee, W. L. & Lindblad, A. S. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 63, 1705–1707 (2004).
  CAS PubMed Google Scholar
• Petersen, R. C. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352, 2379–2388 (2005).
  CAS PubMed Google Scholar
• Sano, M. et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336, 1216–1222 (1997).
  CAS PubMed Google Scholar
• Chiu, C. C. et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1538–1544 (2008).
  CAS PubMed Google Scholar
• Freund-Levi, Y. et al. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dement. Geriatr. Cogn. Disord. 27, 481–490 (2009).
  CAS PubMed Google Scholar
• Nagano, S. et al. Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links β-amyloid (Aβ) and generates Aβ–COX-2 hetero-oligomers that are increased in Alzheimer's disease. J. Biol. Chem. 279, 14673–14678 (2004).
  CAS PubMed Google Scholar
• Butterfield, D. A., Castegna, A., Drake, J., Scapagnini, G. & Calabrese, V. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr. Neurosci. 5, 229–239 (2002).
  CAS PubMed Google Scholar
• Pitchumoni, S. S. & Doraiswamy, P. M. Current status of antioxidant therapy for Alzheimer's Disease. J. Am. Geriatr. Soc. 46, 1566–1572 (1998).
  CAS PubMed Google Scholar
• Weisburger, J. H. Vitamin C and prevention of nitrosamine formation. Lancet 2, 607 (1977).
  CAS PubMed Google Scholar
• Pardo, B., Mena, M. A., Fahn, S. & Garcia de Yebenes, J. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov. Disord. 8, 278–284 (1993).
  CAS PubMed Google Scholar
• Voko, Z., Hollander, M., Hofman, A., Koudstaal, P. J. & Breteler, M. M. Dietary antioxidants and the risk of ischemic stroke: the Rotterdam Study. Neurology 61, 1273–1275 (2003).
  CAS PubMed Google Scholar
• Calder, P. C. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 36, 1007–1024 (2001).
  CAS PubMed Google Scholar
• Yehuda, S., Rabinovitz, S., Carasso, R. L. & Mostofsky, D. I. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol. Aging 23, 843–853 (2002).
  CAS PubMed Google Scholar
• Abbott, R. D. et al. Walking and dementia in physically capable elderly men. JAMA 292, 1447–1453 (2004).
  CAS PubMed Google Scholar
• Fratiglioni, L., Paillard-Borg, S. & Winblad, B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 3, 343–353 (2004).
  PubMed Google Scholar
• Scarmeas, N., Levy, G., Tang, M. X., Manly, J. & Stern, Y. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology 57, 2236–2242 (2001).
  CAS PubMed Google Scholar
• Verghese, J. et al. Leisure activities and the risk of dementia in the elderly. N. Engl. J. Med. 348, 2508–2516 (2003).
  PubMed Google Scholar
• Rovio, S. et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 4, 705–711 (2005).
  PubMed Google Scholar
• Churchill, J. D. et al. Exercise, experience and the aging brain. Neurobiol. Aging 23, 941–955 (2002).
  PubMed Google Scholar
• Colcombe, S. & Kramer, A. F. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol. Sci. 14, 125–130 (2003).
  PubMed Google Scholar
• Dishman, R. K. et al. Neurobiology of exercise. Obesity 14, 345–356 (2006).
  CAS PubMed Google Scholar
• Emery, C. F., Schein, R. L., Hauck, E. R. & MacIntyre, N. R. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. Health Psychol. 17, 232–240 (1998).
  CAS PubMed Google Scholar
• Fabre, C., Chamari, K., Mucci, P., Masse-Biron, J. & Prefaut, C. Improvement of cognitive function by mental and/or individualized aerobic training in healthy elderly subjects. Int. J. Sports Med. 23, 415–421 (2002).
  CAS PubMed Google Scholar
• Kramer, A. F., Erickson, K. I. & Colcombe, S. J. Exercise, cognition, and the aging brain. J. Appl. Physiol. 101, 1237–1242 (2006).
  PubMed Google Scholar
• Lautenschlager, N. T. et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300, 1027–1037 (2008).
  CAS PubMed Google Scholar
• Angevaren, M., Aufdemkampe, G., Verhaar, H. J., Aleman, A. & Vanhees, L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD005381. doi:10.1002/14651858. CD005381.pub3 (2008).
• Carlson, M. C. et al. Midlife activity predicts risk of dementia in older male twin pairs. Alzheimers Dement. 4, 324–331 (2008).
  PubMed PubMed Central Google Scholar
• Fratiglioni, L. & Wang, H. X. Brain reserve hypothesis in dementia. J. Alzheimers Dis. 12, 11–22 (2007).
  PubMed Google Scholar
• Acevedo, A. & Loewenstein, D. A. Nonpharmacological cognitive interventions in aging and dementia. J. Geriatr. Psychiatry Neurol. 20, 239–249 (2007).
  PubMed Google Scholar
• Ball, K. et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 288, 2271–2281 (2002).
  PubMed PubMed Central Google Scholar
• Unverzagt, F. W. et al. Effect of memory impairment on training outcomes in ACTIVE. J. Int. Neuropsychol. Soc. 13, 953–960 (2007).
  PubMed PubMed Central Google Scholar
• Alzheimer Disease Mutation Database. Alzheimer Disease & Frontotemporal Dementia Mutation Database [online], (2010).
• De Strooper, B. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387–390 (1998).
  CAS PubMed Google Scholar
• Scheuner, D. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864–870 (1996).
  CAS PubMed Google Scholar
• Green, R. C. et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 287, 329–336 (2002).
  PubMed Google Scholar
• Gatz, M. et al. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63, 168–174 (2006).
  PubMed Google Scholar
• Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921–923 (1993).
  CAS PubMed Google Scholar
• Kurz, A. et al. Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. J. Neurol. 243, 452–456 (1996).
  CAS PubMed Google Scholar
• Poirier, J. et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342, 697–699 (1993).
  CAS PubMed Google Scholar
• Farlow, M. R. et al. Impact of APOE in mild cognitive impairment. Neurology 63, 1898–1901 (2004).
  CAS PubMed Google Scholar
• Myers, R. H. et al. Apolipoprotein E ɛ4 association with dementia in a population-based study: the Framingham study. Neurology 46, 673–677 (1996).
  CAS PubMed Google Scholar
• Daw, E. W. et al. The number of trait loci in late-onset Alzheimer disease. Am. J. Hum. Genet. 66, 196–204 (2000).
  CAS PubMed Google Scholar
• Rogaeva, E. et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genet. 39, 168–177 (2007).
  CAS PubMed Google Scholar
• Reitz, C. et al. Meta-analysis of the association between variants in SORL1 and Alzheimer's disease. Arch. Neurol. 68, 99–106 (2011).
  PubMed PubMed Central Google Scholar
• Reitz, C. et al. SORCS1 alters APP processing and variants may increase Alzheimer's disease risk. Ann. Neurol. doi:10.1002/ana.22308.
  CAS PubMed PubMed Central Google Scholar
• Lane, R. et al. Diabetes-associated SorCS1 regulates Alzheimer's amyloid-β metabolism: evidence for involvement of SorL1 and the retromer complex. J. Neurosci. 30, 13110–13115 (2010).
  CAS PubMed PubMed Central Google Scholar
• Beecham, G. W. et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am. J. Hum. Genet. 84, 35–43 (2009).
  CAS PubMed PubMed Central Google Scholar
• Bertram, L., McQueen, M. B., Mullin, K., Blacker, D. & Tanzi, R. E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39, 17–23 (2007).
  CAS PubMed Google Scholar
• Carrasquillo, M. M. et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat. Genet. 41, 192–198 (2009).
  CAS PubMed PubMed Central Google Scholar
• Reiman, E. M. et al. GAB2 alleles modify Alzheimer's risk in APOE ɛ4 carriers. Neuron 54, 713–720 (2007).
  CAS PubMed PubMed Central Google Scholar
• Potkin, S. G. et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One 4, e6501 (2009).
  PubMed PubMed Central Google Scholar
• Harold, D. et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41, 1088–1093 (2009).
  CAS PubMed PubMed Central Google Scholar
• Lambert, J. C. et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094–1099 (2009).
  CAS PubMed Google Scholar
• Bertrand, P., Poirier, J., Oda, T., Finch, C. E. & Pasinetti, G. M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol. Brain Res. 33, 174–178 (1995).
  CAS PubMed Google Scholar
• Wyss-Coray, T. et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl Acad. Sci. USA 99, 10837–10842 (2002).
  CAS PubMed PubMed Central Google Scholar
• Baig, S. et al. Distribution and expression of picalm in Alzheimer disease. J. Neuropathol. Exp. Neurol. 69, 1071–1077 (2010).
  CAS PubMed Google Scholar
• Seshadri, S. et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303, 1832–1840 (2010).
  CAS PubMed PubMed Central Google Scholar
• Wigge, P. et al. Amphiphysin heterodimers: potential role in clathrin-mediated endocytosis. Mol. Biol. Cell 8, 2003–2015 (1997).
  CAS PubMed PubMed Central Google Scholar
• Kelly, B. L. & Ferreira, A. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience 147, 60–70 (2007).
  CAS PubMed Google Scholar
• Yang, S. et al. Comparative proteomic analysis of brains of naturally aging mice. Neuroscience 154, 1107–1120 (2008).
  CAS PubMed Google Scholar
• Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E. M. & Mandelkow, E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89, 297–308 (1997).
  CAS PubMed Google Scholar
• Starcevic, M. & Dell'Angelica, E. C. Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1). J. Biol. Chem. 279, 28393–28401 (2004).
  CAS PubMed Google Scholar
• Morris, D. W. et al. Dysbindin (DTNBP1) and the biogenesis of lysosome-related organelles complex 1 (BLOC-1): main and epistatic gene effects are potential contributors to schizophrenia susceptibility. Biol. Psychiatry 63, 24–31 (2008).
  CAS PubMed Google Scholar
• Hansson, O. et al. Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23, 316–320 (2007).
  CAS PubMed Google Scholar
• Ewers, M. et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69, 2205–2212 (2007).
  CAS PubMed Google Scholar
• Andersson, C. et al. Differential CSF biomarker levels in _APOE_-ɛ4-positive and -negative patients with memory impairment. Dement. Geriatr. Cogn. Disord. 23, 87–95 (2007).
  CAS PubMed Google Scholar
• Hoglund, K. et al. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated β-amyloid peptides. Neurodegener. Dis. 5, 268–276 (2008).
  CAS PubMed Google Scholar
• Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 59, 512–519 (2006).
  CAS PubMed Google Scholar
• Buerger, K. et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035–3041 (2006).
  PubMed Google Scholar
• Buerger, K. et al. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 130, e82 (2007).
  PubMed Google Scholar
• Engelborghs, S. et al. No association of CSF biomarkers with APOEɛ4, plaque and tangle burden in definite Alzheimer's disease. Brain 130, 2320–2326 (2007).
  PubMed Google Scholar
• Fukumoto, H. et al. Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch. Neurol. 60, 958–964 (2003).
  PubMed Google Scholar
• Shafaati, M., Solomon, A., Kivipelto, M., Bjorkhem, I. & Leoni, V. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neurosci. Lett. 425, 78–82 (2007).
  CAS PubMed Google Scholar
• Schmand, B., Huizenga, H. M. & van Gool, W. A. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol. Med. 40, 135–145 (2010).
  CAS PubMed Google Scholar
• Kosaka, T. et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 48, 741–745 (1997).
  CAS PubMed Google Scholar
• Schupf, N. et al. Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome. Neurosci. Lett. 301, 199–203 (2001).
  CAS PubMed Google Scholar
• Mayeux, R. et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61, 1185–1190 (2003).
  CAS PubMed Google Scholar
• van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J. & Breteler, M. M. Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case–cohort study. Lancet Neurol. 5, 655–660 (2006).
  CAS PubMed Google Scholar
• Lopez, O. L. et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70, 1664–1671 (2008).
  CAS PubMed Google Scholar
• Lui, J. K. et al. Plasma amyloid-β as a biomarker in Alzheimer's disease: the AIBL study of aging. J. Alzheimers Dis. 20, 1233–1242 (2010).
  CAS PubMed Google Scholar
• Schupf, N. et al. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl Acad. Sci. USA 105, 14052–14057 (2008).
  CAS PubMed PubMed Central Google Scholar
• Teipel, S. J. et al. Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. Am. J. Psychiatry 160, 1870–1878 (2003).
  PubMed Google Scholar
• Karas, G. et al. Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology 49, 967–976 (2007).
  PubMed Google Scholar
• Krasuski, J. S. et al. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biol. Psychiatry 43, 60–68 (1998).
  CAS PubMed Google Scholar
• Mungas, D. et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 65, 565–571 (2005).
  CAS PubMed Google Scholar
• Apostolova, L. G. et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch. Neurol. 63, 693–699 (2006).
  PubMed Google Scholar
• Likeman, M. et al. Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. Arch. Neurol. 62, 1410–1415 (2005).
  PubMed Google Scholar
• Chetelat, G. et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 27, 934–946 (2005).
  CAS PubMed Google Scholar
• Rombouts, S. A. et al. Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am. J. Neuroradiol. 21, 1869–1875 (2000).
  CAS PubMed PubMed Central Google Scholar
• Small, G. W. et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 7, 161–172 (2008).
  PubMed PubMed Central Google Scholar
• Silverman, D. H. et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286, 2120–2127 (2001).
  CAS PubMed Google Scholar
• O'Brien, J. T. Role of imaging techniques in the diagnosis of dementia. Br. J. Radiol. 80, S71–S77 (2007).
  PubMed Google Scholar
• Klunk, W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306–319 (2004).
  CAS PubMed Google Scholar
• Engler, H. et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856–2866 (2006).
  PubMed Google Scholar
• Frisoni, G. B. et al. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 72, 1504–1511 (2009).
  CAS PubMed Google Scholar
• Tolboom, N. et al. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology 73, 2079–2085 (2009).
  CAS PubMed Google Scholar
• Katzman, R. Editorial: the prevalence and malignancy of Alzheimer disease. A major killer. Arch. Neurol. 33, 217–218 (1976).
  CAS PubMed Google Scholar